- Home
- ALNY vs CCEP Comparison
ALNY vs CCEP Comparison
Compare ALNY & CCEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALNY | CCEP |
|---|---|---|
| Founded | 2002 | 1986 |
| Country | United States | United Kingdom |
| Employees | 115 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Beverages (Production/Distribution) |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.8B | 43.1B |
| IPO Year | 2004 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ALNY | CCEP |
|---|---|---|
| Price | $291.27 | $92.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 28 | 6 |
| Target Price | ★ $471.00 | $104.33 |
| AVG Volume (30 Days) | 1.0M | ★ 1.4M |
| Earning Date | 04-30-2026 | 02-17-2026 |
| Dividend Yield | N/A | ★ 2.48% |
| EPS Growth | ★ 206.88 | N/A |
| EPS | ★ 2.33 | N/A |
| Revenue | ★ $1,037,418,000.00 | N/A |
| Revenue This Year | $52.67 | $4.86 |
| Revenue Next Year | $31.48 | $3.79 |
| P/E Ratio | $122.99 | ★ $20.93 |
| Revenue Growth | ★ 22.88 | N/A |
| 52 Week Low | $284.19 | $84.66 |
| 52 Week High | $495.55 | $110.90 |
Technical Indicators
Market Signals| Indicator | ALNY | CCEP |
|---|---|---|
| Relative Strength Index (RSI) | 39.13 | 42.64 |
| Support Level | N/A | $89.83 |
| Resistance Level | $322.26 | $93.00 |
| Average True Range (ATR) | 11.27 | 2.00 |
| MACD | -1.36 | -0.20 |
| Stochastic Oscillator | 19.23 | 13.35 |
Price Performance
Historical ComparisonAbout ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
About CCEP Coca-Cola Europacific Partners plc
CCEP is the second-largest bottling partner in the Coca-Cola system by volume, behind Coca-Cola Femsa, and primarily operates in developed Europe, Australasia, and Southeast Asia. In 2025, CCEP sold 3.9 billion unit cases of beverages, which we estimate equates to roughly 9% of the global Coke system volume.TCCC owns 19% of the equity of CCEP, Olive Partners, a holding company of bottling operations, owns a further 36%, and the remaining 45% is free float.